{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:13:22Z","timestamp":1792782802198,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T00:00:00Z","timestamp":1582675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T00:00:00Z","timestamp":1582675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Novartis Pharma AG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Family planning is an important consideration for women with multiple sclerosis (MS), who are often diagnosed during their reproductive years. Currently, limited data are available on pregnancy outcomes in patients exposed to interferon-beta (IFN-beta) before or during pregnancy. Here, we present the cumulative pregnancy exposure data and prevalence of pregnancy and infant outcomes in IFN-beta-exposed pregnant women with MS from the European IFN-beta Pregnancy Registry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using spontaneous and solicited reports, the registry collected data from 26 countries of the European Economic Area, consisting of information on women with MS identifying themselves to one of the Marketing Authorisation Holders (Bayer, Biogen, Merck KGaA, and Novartis) or healthcare professionals as pregnant and exposed to IFN-beta during pregnancy or within 1\u00a0month before conception. The outcomes collected by the registry included ectopic pregnancies, spontaneous abortions, elective terminations, live, and stillbirths with or without congenital anomalies. The prevalence of pregnancy outcomes was put in context with those reported in the general population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between 2009 and 2017, the registry collected 948 pregnancy reports with a known pregnancy outcome. Overall, 82.0% (777\/948) of pregnancies resulted in live birth without congenital anomaly. When comparing IFN-beta-exposed pregnancies with the general population, the prevalence of spontaneous abortions (10.7% vs. 10\u201321%) and congenital anomalies in live births (2.1% vs. 2.1\u20134.1%) were found to be within reported ranges.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The data gathered from these pregnancy cases suggest no evidence that IFN-beta exposure before conception and\/or during pregnancy adversely increases the rate of congenital anomalies or spontaneous abortions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00415-020-09762-y","type":"journal-article","created":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T00:32:33Z","timestamp":1582677153000},"page":"1715-1723","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry"],"prefix":"10.1007","volume":"267","author":[{"name":"the European Interferon-beta Pregnancy Study Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4467-9011","authenticated-orcid":false,"given":"Kerstin","family":"Hellwig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Geissbuehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meritxell","family":"Sabid\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catrinel","family":"Popescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Adamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Klinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asher","family":"Ornoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Huppke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,26]]},"reference":[{"issue":"2","key":"9762_CR1","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s40263-018-0496-6","volume":"32","author":"C Vaughn","year":"2018","unstructured":"Vaughn C, Bushra A, Kolb C, Weinstock-Guttman B (2018) An update on the use of disease-modifying therapy in pregnant patients with multiple sclerosis. CNS Drugs 32(2):161\u2013178","journal-title":"CNS Drugs"},{"issue":"2","key":"9762_CR2","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/ene.13536","volume":"25","author":"X Montalban","year":"2018","unstructured":"Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D et al (2018) ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Eur J Neurol 25(2):215\u2013237","journal-title":"Eur J Neurol"},{"issue":"2","key":"9762_CR3","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/1352458517751049","volume":"24","author":"X Montalban","year":"2018","unstructured":"Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D et al (2018) ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler 24(2):96\u2013120","journal-title":"Mult Scler"},{"key":"9762_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2018-002060","author":"R Dobson","year":"2019","unstructured":"Dobson R, Dassan P, Roberts M, Giovannoni G, Nelson-Piercy C, Brex PA (2019) UK consensus on pregnancy in multiple sclerosis: \u2018Association of British Neurologists\u2019 guidelines. Pract Neurol. https:\/\/doi.org\/10.1136\/practneurol-2018-002060","journal-title":"Pract Neurol"},{"issue":"11","key":"9762_CR5","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1212\/WNL.0b013e3182698c64","volume":"79","author":"E Lu","year":"2012","unstructured":"Lu E, Wang BW, Guimond C, Synnes A, Sadovnick D, Tremlett H (2012) Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurology 79(11):1130\u20131135","journal-title":"Neurology"},{"issue":"6","key":"9762_CR6","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1177\/1352458516634872","volume":"22","author":"S Thiel","year":"2016","unstructured":"Thiel S, Langer-Gould A, Rockhoff M, Haghikia A, Queisser-Wahrendorf A, Gold R et al (2016) Interferon-beta exposure during first trimester is safe in women with multiple sclerosis\u2014a prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry. Mult Scler 22(6):801\u2013809","journal-title":"Mult Scler"},{"issue":"8","key":"9762_CR7","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1007\/s00415-008-0909-4","volume":"255","author":"F Patti","year":"2008","unstructured":"Patti F, Cavallaro T, Lo Fermo S, Nicoletti A, Cimino V, Vecchio R et al (2008) Is in utero early-exposure to interferon beta a risk factor for pregnancy outcomes in multiple sclerosis? J Neurol 255(8):1250\u20131253","journal-title":"J Neurol"},{"issue":"20","key":"9762_CR8","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1212\/WNL.0b013e3181fd62bb","volume":"75","author":"MP Amato","year":"2010","unstructured":"Amato MP, Portaccio E, Ghezzi A, Hakiki B, Zipoli V, Martinelli V et al (2010) Pregnancy and fetal outcomes after interferon-\u03b2 exposure in multiple sclerosis. Neurology 75(20):1794\u20131802","journal-title":"Neurology"},{"key":"9762_CR9","first-page":"1034912","volume":"2016","author":"R Alroughani","year":"2016","unstructured":"Alroughani R, Altintas A, Al Jumah M, Sahraian M, Alsharoqi I, AlTahan A et al (2016) Pregnancy and the use of disease-modifying therapies in patients with multiple sclerosis: benefits versus risks. Mult Scler Int 2016:1034912","journal-title":"Mult Scler Int"},{"issue":"5","key":"9762_CR10","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1080\/14740338.2017.1311321","volume":"16","author":"J Thone","year":"2017","unstructured":"Thone J, Thiel S, Gold R, Hellwig K (2017) Treatment of multiple sclerosis during pregnancy\u2014safety considerations. Expert Opin Drug Saf 16(5):523\u2013534","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"9762_CR11","doi-asserted-by":"publisher","first-page":"e004536","DOI":"10.1136\/bmjopen-2013-004536","volume":"4","author":"PK Coyle","year":"2014","unstructured":"Coyle PK, Sinclair SM, Scheuerle AE, Thorp JM Jr, Albano JD, Rametta MJ (2014) Final results from the Betaseron (interferon beta-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events. BMJ Open 4(5):e004536","journal-title":"BMJ Open"},{"issue":"5","key":"9762_CR12","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1177\/1756285612453192","volume":"5","author":"K Hellwig","year":"2012","unstructured":"Hellwig K, Haghikia A, Rockhoff M, Gold R (2012) Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. Ther Adv Neurol Disord 5(5):247\u2013253","journal-title":"Ther Adv Neurol Disord"},{"issue":"5","key":"9762_CR13","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1136\/jnnp-2014-308113","volume":"86","author":"RS Romero","year":"2015","unstructured":"Romero RS, Lunzmann C, Bugge JP (2015) Pregnancy outcomes in patients exposed to interferon beta-1b. J Neurol Neurosurg Psychiatry 86(5):587\u2013589","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"9762_CR14","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1177\/1352458510394610","volume":"17","author":"M Sandberg-Wollheim","year":"2011","unstructured":"Sandberg-Wollheim M, Alteri E, Moraga MS, Kornmann G (2011) Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy. Mult Scler 17(4):423\u2013430","journal-title":"Mult Scler"},{"issue":"9","key":"9762_CR15","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1177\/1352458509106543","volume":"15","author":"C Weber-Schoendorfer","year":"2009","unstructured":"Weber-Schoendorfer C, Schaefer C (2009) Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. Mult Scler 15(9):1037\u20131042","journal-title":"Mult Scler"},{"key":"9762_CR16","unstructured":"EMEA\/CHMP\/313666\/2005 (2005) Committee for medicinal products for human use (CHMP): guideline on the exposure to medicinal products during pregnancy: need for post-authorisation data. https:\/\/www.ema.europa.eu\/documents\/regulatory-procedural-guideline\/guideline-exposure-medicinal-products-during-pregnancy-need-post-authorisation-data_en.pdf. Accessed 16 Jan 2019."},{"key":"9762_CR17","unstructured":"World Health Organisation (2016) Congenital anomalies fact sheet. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/congenital-anomalies. Accessed 09 May 2019."},{"issue":"4","key":"9762_CR18","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1080\/00016340500494887","volume":"85","author":"L Buss","year":"2006","unstructured":"Buss L, Tolstrup J, Munk C, Bergholt T, Ottesen B, Gronbaek M et al (2006) Spontaneous abortion: a prospective cohort study of younger women from the general population in Denmark. Validation, occurrence and risk determinants. Acta Obstet Gynecol Scand 85(4):467\u2013475","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"3","key":"9762_CR19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.21101\/cejph.a3893","volume":"22","author":"Z Irisa","year":"2014","unstructured":"Irisa Z, Vi IA, Gissler M (2014) Monitoring of congenital anomalies in Latvia. Cent Eur J Public Health 22(3):147\u2013152","journal-title":"Cent Eur J Public Health"},{"key":"9762_CR20","unstructured":"EUROCAT (2019) European Surveillance of Congenital Anomalies, prevalence data tables. https:\/\/www.eurocat-network.eu\/ACCESSPREVALENCEDATA\/PrevalenceTables. Accessed 16 Jan 2019."},{"key":"9762_CR21","unstructured":"Congenital Malformations Registry (2005) Summary report: statistical summary of children born in 1998\u20132001 and diagnosed through 2003. https:\/\/www.health.ny.gov\/diseases\/congenital_malformations\/docs\/98report.pdf. Accessed 16 Jan 2019"},{"issue":"3","key":"9762_CR22","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00404-001-0265-4","volume":"266","author":"A Queisser-Luft","year":"2002","unstructured":"Queisser-Luft A, Stolz G, Wiesel A, Schlaefer K, Spranger J (2002) Malformations in newborn: results based on 30,940 infants and fetuses from the Mainz congenital birth defect monitoring system (1990\u20131998). Arch Gynecol Obstet 266(3):163\u2013167","journal-title":"Arch Gynecol Obstet"},{"issue":"2","key":"9762_CR23","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1093\/humrep\/deh078","volume":"19","author":"JX Wang","year":"2004","unstructured":"Wang JX, Norman RJ, Wilcox AJ (2004) Incidence of spontaneous abortion among pregnancies produced by assisted reproductive technology. Hum Reprod 19(2):272\u2013277","journal-title":"Hum Reprod"},{"key":"9762_CR24","first-page":"471","volume-title":"Birth defects: the developing human: clinically oriented embryology","author":"KL Moore","year":"2012","unstructured":"Moore KL, Persaud TVN, Torchia MG (2012) Birth defects: the developing human: clinically oriented embryology. Saunders, Philadelphia, pp 471\u2013500"},{"issue":"1","key":"9762_CR25","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/j.1365-2125.2012.04185.x","volume":"74","author":"G Moulis","year":"2012","unstructured":"Moulis G, Sommet A, Durrieu G, Bagheri H, Lapeyre-Mestre M, Montastruc JL (2012) Trends of reporting of 'serious' vs. 'non-serious' adverse drug reactions over time: a study in the French PharmacoVigilance Database. Br J Clin Pharmacol 74(1):201\u2013204","journal-title":"Br J Clin Pharmacol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-020-09762-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-020-09762-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-020-09762-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T19:08:13Z","timestamp":1614193693000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-020-09762-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,26]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["9762"],"URL":"https:\/\/doi.org\/10.1007\/s00415-020-09762-y","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,26]]},"assertion":[{"value":"14 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"KH has received honoraria and research support from Bayer, Biogen, Teva, Novartis, Sanofi Genzyme, and Merck KGaA. YG is an employee of Novartis Pharma AG. MS is an employee of Merck Healthcare KGaA, Darmstadt, Germany. CP is an employee of Biogen. AA is an employee of Bayer AG. JK is an employee of SynteractHCR GmbH. PH has received honoraria and research support from Bayer, Biogen, Novartis, and Merck KGaA, and is a member of the European Interferon-beta Pregnancy Study Group. AO has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This article is based on a prospective observational collection of data from women exposed to IFN-beta before and\/or during pregnancy and their pregnancy outcomes, and does not contain any studies with human participants performed by any of the authors<b>.<\/b>","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}